Zhou Fang J, Yu Shao L, Li Yong H, Liu Zhuo W, Xiong Yong H, Wu Pei H, Han Hui, Qin Zi K
Department of Urology, Cancer Center, Sun Yat-Sen University, Guangzhou, China.
J Chemother. 2009 Feb;21(1):91-7. doi: 10.1179/joc.2009.21.1.91.
Post-cystectomy recurrence of transitional-cell carcinoma (TCC) that is confined to the pelvis is uncommon, and few data exist to guide its management. we used weekly intra-arterial chemotherapy with gemcitabine and cisplatin in a consecutive series of 11 patients with this diagnosis. After 2 cycles of intra-arterial chemotherapy with gemcitabine (each cycle: 900 mg/m(2) on days 1, 8, and 15) plus cisplatin (each cycle: 30 mg/m(2) on days 1, 8, and 15), 3 patients achieved complete response (CR) and 8 patients partial response (PR). two pR patients achieved CR after surgery and radiotherapy for residual disease. Six pR patients died of disease progression 8 to 20 months after chemotherapy. Four CR patients have survived, free of disease, 17 to 43 months, and 1 CR patient died of a non-tumor-related cause 23 months after chemotherapy. Short course intra-arterial chemotherapy with a GC regimen thus appears to be highly effective in the subset of patients with recurrent TCC confined to the pelvis.
局限于盆腔的移行细胞癌(TCC)膀胱切除术后复发并不常见,且几乎没有数据可指导其治疗。我们对连续的11例诊断为此病的患者采用吉西他滨和顺铂进行每周一次的动脉内化疗。在进行2个周期的吉西他滨(每个周期:第1、8和15天给予900mg/m²)加顺铂(每个周期:第1、8和15天给予30mg/m²)动脉内化疗后,3例患者达到完全缓解(CR),8例患者达到部分缓解(PR)。2例PR患者在针对残留病灶进行手术和放疗后达到CR。6例PR患者在化疗后8至20个月死于疾病进展。4例CR患者已无病存活17至43个月,1例CR患者在化疗后23个月死于非肿瘤相关原因。因此,采用GC方案的短程动脉内化疗在局限于盆腔的复发性TCC患者亚组中似乎非常有效。